71 results about "Nociception" patented technology

The invention relates to the determination of the anesthetic state of a patient. In order to achieve a mechanism that enables establishment and maintenance of balanced anesthesia, values are established for a set of diagnostic indices. The set includes at least two diagnostic indices of which a first diagnostic index is indicative of the level of hypnosis and a second diagnostic index of the level of nociception in the patient. The combination of the at least two index values obtained is employed for indicating the anesthetic state of the patient. The combination of the at least two index values may further be employed to control the administration of drugs to the patient.

The invention relates to the determination of the clinical state of a subject. In order to bring about an uncomplicated method for monitoring the clinical state of a subject and for accomplishing a diagnostic scale, such as a nociception scale, on which a certain reading corresponds to the same level for all patients, a normalization transform is applied to a measurement signal containing physiological data obtained from a patient, whereby a normalized measurement signal having a predetermined value range is obtained. The normalization transform is dependent on predetermined history data, such as previous signal data of said measurement signal. A diagnostic index dependent on the normalized measurement signal is then formed, the diagnostic index serving as a measure of the clinical state of the patient. The diagnostic index may be formed based on one or more normalized measurement signals.

The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with nociception or taste disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.

This invention provides compounds which are represented by a general formula [I][in which X stands for hydrogen or halogen; B stands for halogen, cyano or optionally fluorine-substituted lower alkyl; D stands for a 3–10 membered aliphatic nitrogen-containing heterocyclic group; R3, R4 and R5 may be same or different, and each stands for hydrogen, lower alkyl optionally having substituent group(s) and the like; and a is 0 or 1]. These compounds exhibit high affinity to nociceptin receptors and whereby inhibit actions of nociceptin, and are useful as an analgesic, antiobestic, agent for ameliorating brain function, treating agents for Alzheimer's disease and dementia, and therapeutic agents for schizophrenia, neurodegenerative diseases, depression, diabetes insipidus, polyuria, hypotension and the like.

The invention relates to the determination of the anesthetic state of a patient. In order to achieve a mechanism that enables establishment and maintenance of balanced anesthesia, values are established for a set of diagnostic indices. The set includes at least two diagnostic indices of which a first diagnostic index is indicative of the level of hypnosis and a second diagnostic index of the level of nociception in the patient. The combination of the at least two index values obtained is employed for indicating the anesthetic state of the patient. The combination of the at least two index values may further be employed to control the administration of drugs to the patient.

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and / or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and / or nociception in an individual.

Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a NaV1.7 channel protein or a complete humanization of an endogenous NaV1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric NaV1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric NaV1.7 protein the cell surface. In vivo and in vitro methods for characterizing NaV1.7-specific antagonists and evaluation of corresponding therapeutic potential for NaV1.7-mediated disease are also provided.

The present invention disclosed a device and method for assessing in real time the hypnotic and analgesic effect in a subject during wakefulness, sedation and general anaesthesia via drug interactions and physiological signals. In a preferred embodiment of the present invention, the analgesic and hypnotic effect of drug(s) infused in a subject could be accurately assessed in real time through the device and method disclosed in the present invention, comprising steps of receiving data from electroencephalography (EEG) device, receiving data from brain impedance tomography device, obtaining pharmacodynamic and pharmacokinetic parameters of drug(s) infused in the subject, defining initial indices of consciousness and nociception as a function of said EEG and brain impedance tomography data, and generating output of final indices of consciousness and nociception in real time from processing input of EEG, brain tomography and drug interaction data using established mathematical manipulation.

The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.

The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia

Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and / or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing a compound for the treatment of pain, the reduction of nociception and the diagnosis and prognostication of pain are also described.

Disclosed are compounds of the formula (I)wherein A, R1, R2, R3, R4 and X1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chronic and acute pain.

The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.

The invention described below relates to the discovery of the neuropeptide FF receptor subtype that mediates acute nociception and chronic neuropathic pain, compounds that selectively interact with this receptor subtype and methods for treating acute pain and chronic neuropathic pain.

The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and / or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and / or nociception in an individual.

Disclosed are compounds of the formula (I) wherein A, R1, R2, R3, R4 and X1 are as disclosed herein. The compounds have affinity for the ORL1 receptor and are useful in the treatment of chronic and acute pain.

The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scrtaching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a NaV1.7 channel protein or a complete humanization of an endogenous NaV1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric NaV1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric NaV1.7 protein the cell surface. In vivo and in vitro methods for characterizing NaV1.7-specific antagonists and evaluation of corresponding therapeutic potential for NaV1.7-mediated disease are also provided.

The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the Targeting Moiety is selected from the group consisting of BAM, β-endorphin, bradykinin, substance P, dynorphin and / or nociceptin.

The invention provides an application of a peptide containing an amino acid sequence YEKLLDTEI or functional variants thereof or pharmaceutical composition containing the peptide in preparation of drugs for preventing, relieving or treating pain, particularly nociceptive pain as well as a method for preventing, relieving or treating the pain.

The invention relates to the determination of the clinical state of a subject. In order to bring about an uncomplicated method for monitoring the clinical state of a subject and for accomplishing a diagnostic scale, such as a nociception scale, on which a certain reading corresponds to the same level for all patients, a normalization transform is applied to a measurement signal containing physiological data obtained from a patient, whereby a normalized measurement signal having a predetermined value range is obtained. The normalization transform is dependent on predetermined history data, such as previous signal data of said measurement signal. A diagnostic index dependent on the normalized measurement signal is then formed, the diagnostic index serving as a measure of the clinical state of the patient. The diagnostic index may be formed based on one or more normalized measurement signals.

The present invention relates to a compound of the formula [1′] wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.

The present invention relates to an antipruritic agent comprising a nociceptine antagonist as an active ingredient. The nociceptine antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney dialysis, diabetes, blood disease, liver disease, kidney disease, incretion and metabolic disorder, viscera malignant tumor, hyperthyroidism, autoimmune disease, multiple sclerosis, neurologic disease, psychoneurosis, allergic conjunctivitis, spring catarrh, atopic keratoconjunctivitis, or itching caused by excess use of laxuries and drugs because it has excellent scratching behavior suppressing effect, that is, antiitching effect and antipruritic effect.

The invention aims to provide application of an inhibitor SB (Sodium Butyrate) 203580 of p (phosphor)-p38. Activation of phosphor-p38 mediated microglial cells contributes to pain correlated responses of a pain model of BmKI (Biomedical Knowledge Integration); the specific inhibitor SB 203580 of the p-p38 can inhibit the microglial cell and thus relieving the pain correlated responses in the pain model of the BmKI. The invention provides a theoretical basis for pain central sensitization induced by peripheral damages, a study carrier for studying cellular and molecular mechanisms and treatment strategies of nociception and an experimental basis for studying novel drugs for relieving the pain on clinic are provided. The SB 203580 has a prospect of becoming a tool medicine applied in studying correlated pain mechanism of p38 signal path and then has a potential prospect of developing drugs for treating and relieving pathological pain and maintaining corresponding drugs on clinic.

The present invention relates to a method for the management of pain associated with sickle cell disease. In particular, the method comprises administering to a patient in need of such pain management a therapeutically effective amount of a nociceptin (NOP) receptor agonist or an NOP receptor agonist / mu opioid receptor (MOR) partial agonist.